We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals
GLMD

12 hedge funds and large institutions have $429K invested in Galmed Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

50% more funds holding

Funds holding: 8 → 12 (+4)

2% more capital invested

Capital invested by funds: $419K → $429K (+$10.1K)

0.1% more ownership

Funds ownership: 0.09% → 0.19% (+0.1%)

Holders
12
Holders Change
+4
Holders Change %
+50%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
+$276K
2
CH
CVI Holdings
Delaware
+$276K
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$55.9K
4
Citadel Advisors
Citadel Advisors
Florida
+$44.7K
5
Two Sigma Investments
Two Sigma Investments
New York
+$34K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$261K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$74.5K
3
TRCT
Tower Research Capital (TRC)
New York
-$152

GLMD Hedge Fund Activity: Q3 2023 in Review

12 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2023, worth a combined $429K — up 2.4% from $419K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new GLMD positions and 3 closed out — a net gain of 4 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Walleye Capital, opening a new position worth an estimated $276K. The largest seller was BVF Inc, exiting entirely with an estimated $261K sold.

  • 12 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2023, up from 8 in Q2 2023.
  • Funds reported $429K of Galmed Pharmaceuticals stock for Q3 2023, up 2.4% quarter-over-quarter.
  • 7 funds opened new Galmed Pharmaceuticals positions in Q3 2023 and 3 closed out, a net change of +4 holders.
  • The largest Galmed Pharmaceuticals buyer in Q3 2023 was Walleye Capital, an estimated $276K added.
  • The largest Galmed Pharmaceuticals seller in Q3 2023 was BVF Inc, an estimated $261K sold.

Based on aggregated 13F filings for Q3 2023.